Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS‐AP‐Combo

Documenti analoghi

• Correction to “Efficacy and safety in tirzepatide‐treated Korean adults with type 2 diabetes—A post hoc analysis of SURPASS‐AP‐combo and SURPASS‐3”
  Pubblicazione: (2026)
• Achieving normoglycaemia with tirzepatide: Post hoc exploratory analysis of the SURPASS J‐mono and J‐combo studies
  di: Kazuya Fujihara, et al.
  Pubblicazione: (2024)
• Decreased fatty liver index with tirzepatide treatment in Japanese patients with type 2 diabetes: A SURPASS J‐mono post hoc analysis
  di: Masato Yoneda, et al.
  Pubblicazione: (2025)
• Efficacy and safety of chiglitazar add‐on to metformin in type 2 diabetes mellitus ( RECAM study)
  di: Leili Gao, et al.
  Pubblicazione: (2025)
• Improvement in body mass index category was associated with improved cardiometabolic measures and patient‐reported outcomes in adults with type 2 diabetes treated with tirzepatide
  di: Rodolfo J. Galindo, et al.
  Pubblicazione: (2025)